White Paper－The Vigiis 101-LAB, provides bodywide microbiome benefits with just one ingredient
This white paper will expose the remaining untapped market potential for probiotics, as well as the role Vigiis® 101-LAB can play in meeting consumer needs for complete probiotic support across the microbiome.
• USD $78.3 billion will be reached by global probiotics market in 2026
• Constipation affecting 16% of US adults and 33% of US seniors
• COVID-19 has rocketed sales of immune health supplements up 25 percent in 2020, with expected impact in probiotics.
Related posts
White Paper－The ANKASCIN 568-R, safe, effective, and approved red yeast rice extract
According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death globally. Some of the risk factors for CVD include high cholesterol, hypertension and diabetes. Red yeast rice has been shown to help lower cholesterol and improve blood circulation, as well as positively impacting blood lipids, blood glucose and blood pressure. This Whitepaper by SunWay Biotech Co. Ltd. explores the potential of ANKASCIN® 568-R red yeast rice extract—which does not contain monacolin K (statin)—in heart health dietary supplement applications. • The CDC attributes one-quarter of American deaths annually to CVD, with no gender bias. • U.S. sales of red yeast rice dietary supplements were estimated at $49 million in 2015. • The U.S. heart health ingredient market is predicted to reach $15.2 billion by 2018